# Real world Outcomes across the AD spectrum for better care: Multi-modal data Access Platform

@IMI2_ROADMAP
www.roadmap-alzheimer.org

# Background

- Need for innovative treatments in AD (economic, caregiver & societal impact of AD)
- challenges in the evaluation of early disease interventions within the current assessment systems have not changed
- precision medicine approach to health funding requires new models that encompass all the available evidence

# What is ROADMAP?

- Formed under the Innovative Medicines Initiative (IMI2) umbrella
- ROADMAP is a private-public partnership (PPP) to explore the usability of all data sources, in the decision-making process
- It's goal is to develop efficient uses of real world evidence (RWE) for the benefit of AD patients and their caregivers

# ROADMAP Consortium

# ROADMAP Structure



# ROADMAP – Strong data corpus

- **6 European countries** (Denmark, France, Netherlands, Spain, Sweden, UK)
- **75 national databases** and **clinical registries** n≈80M*
- more than **40 cohorts** n≈2M
- several studies using **wearables** and **smart devices** n≈100K
- **5 dementia relevant tria** n≈100K

Leverage existing large data set to perform pilots




*n refers to number of patients

# Expected Key Deliverables

- Define a **minimum set of** measureable **real-world patient outcomes**
- Develop **recommendations on RWE** appropriate AD-related cognitive, functional, and behavioural **endpoints**
- **Identify data sources** and outline a data **integration strategy** for RWE outcomes
- Develop **new methods for collecting RWE data** to improve health care value for AD
- Provide **recommendations for disease progression** and **health economic modelling**
- Under the leadership of UK NICE and the Dutch Regulator (MEB), deliver **guiding principles and recommendations** from HTA groups/payers/regulators for the development and incorporation of RWE into clinical and **market access development plans** for AD

# Funding


“This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.”